Trump’s surgeon general pick to face Senate health committee; Novo Nordisk to slash GLP-1 prices in 2027; Hims & Hers reassures investors despite drug compounding crackdown.

WPP will close the book on a tough 2025 on Thursday (26 February) when chief executive Cindy Rose publishes its annual results and, more importantly, the long-awaited outcome of her strategy review at ...

Dr. Garth Graham brings an unparalleled pedigree to the stage. In addition to his experience at Google and YouTube, Graham served as U.S. Deputy Assistant Secretary for Health under two ...

A pharma PR executive was among the six skiers and three tour guides who died in an avalanche in the Castle Peak area of the Tahoe National Forest, near Truckee, California, on February 17. Danielle ...

Given the copious rules and regulations placed on pharma DTC ads, it’s no wonder tropes abound in the space. And tropes, of course, make things easy to spoof. (Who can forget the faux-warning, “May ...

The second series of Behind the Title, a mental health podcast that interviews leaders across the media industry, has been launched. The inaugural series of the podcast began in September 2025 and has ...

Havas will lead integrated strategy, creative media, and digital efforts across healthcare professional and direct-to-consumer audiences for the Virginia-based drugmaker.

An Accenture spokesperson said: “Our strategy is to be the reinvention partner of choice for our clients and to be the most client-focused, AI-enabled, great place to work. That requires the adoption ...

Gilead drops $7.8B on Arcellx; Pharma lobbyists see an in with the FDA in the Trump 2.0 era; The Trump administration is doubling down on efforts to revamp the federal discount drug program.

South Carolina hospitals aren’t required to disclose measles-related admissions. That leaves doctors in the dark. South Carolina doesn’t require hospitals to report when they admit patients with ...

FDA hones in on antidepressants and RSV prevention; SCOTUS pulls the plug on Trump’s tariffs; GLP-1 turbulence dents Novo’s forecast.

FDA truncates drug approval process; Makary pushes for more OTC drugs; Inside the rocky ride for Recursion Pharmaceuticals.